Transgenic mouse model of AA amyloidosis

Area of Science:

• Biomedical Research
• Genetics
• Pathology

Background:

• AA amyloidosis is a disease characterized by amyloid deposition.
• Current experimental induction methods in mice have limitations, including reliance on exogenous agents and transient deposits.

Purpose of the Study:

• To develop a more robust and reliable in vivo experimental model for studying AA amyloidosis.
• To investigate the potential of a transgenic approach for modeling amyloidosis.

Main Methods:

• Generation of transgenic mice expressing the human interleukin 6 (IL-6) gene under the metallothionein-I promoter.
• Monitoring of serum amyloid A (SAA) protein concentrations and amyloid deposition in organs (spleen, liver, kidneys).
• Radiographic imaging (small-animal CT and MRI) and immunohistochemical/protein sequence analysis to confirm amyloid nature and extent.

Main Results:

• Transgenic mice showed significantly elevated SAA levels.
• Amyloid deposits were observed in the spleen, liver, and kidneys by 3 months of age.
• Extensive amyloidosis was evident at the time of death (approx. 6 months later), confirmed immunohistochemically and by sequence analysis.

Conclusions:

• Transgenic mice overexpressing human IL-6 provide a stable and reproducible in vivo model for AA amyloidosis.
• This model facilitates the assessment of therapeutic strategies for reducing amyloid deposits in AA amyloidosis and related diseases.